NEWSROOM | Galderma

More than skin deep: the daily reality of atopic dermatitis

Galderma unveils final nine-month data showing lasting efficacy and patient satisfaction with its Injectable Aesthetics portfolio when addressing facial aesthetic changes after medication-driven weight loss

Scratching the Surface: shedding light on a misunderstood skin disease

Galderma announces departure of its Chief Financial Officer

Breaking through the surface of sensitive skin

Galderma initiates two new clinical trials investigating nemolizumab in patients with Systemic Sclerosis and Chronic Pruritus of Unknown Origin

Acne Awareness Month: let’s talk about acne

ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years

Galderma establishes new U.S. headquarters in Miami and strengthens regional leadership

Revolutionizing Atopic Dermatitis 2025 Conference: Galderma’s Scientific Presentations

RAD 2025: Long-term data on Nemluvio® (nemolizumab) demonstrate its favorable safety profile and sustained and increased improvements in itch and skin lesions in patients with atopic dermatitis up to two years

International Congress of Dermatology 2025: Galderma’s Scientific Presentations

Galderma buys back shares worth CHF 233 million in the context of accelerated bookbuild offering